Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Part of paid clinical trials in Denver, Colorado.
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
- Study ID
- NCT06239194
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Biliary Tract Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gastric Cancer
- GastroEsophageal Cancer
- Head and Neck Cancer
- Hepatocellular Cancer
- Non-small Cell Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cancer
- Thyroid Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- MDX2001 — DRUGMDX2001 intravenous infusion
Study Details
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Key Dates
- First listed
- Feb 2, 2024
- Start date
- Jun 12, 2024
- Status verified
- May 2026
- Primary completion
- Aug 31, 2028
- Completion
- Feb 28, 2029
Study Design
- Enrollment
- 285 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase 1a - MDX2001 Dose EscalationPatients with metastatic solid tumors will receive MDX2001 as intravenous (IV) infusion.
- Experimental: Phase 1b - Indication OptimizationPatients with a single tumor indication receive MDX2001 as intravenous (IV) infusion.
- Experimental: Phase 1b - Dose OptimizationPatients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion.
- Experimental: Phase 2a - Cohort ExpansionPatients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion at the recommended Phase 2 dose.
Primary Outcome Measure
All Phases: Adverse events (AEs) [ Time Frame: Baseline until end of study, up to approximately 9 months ]
Central Contacts
- Email recommended(857) 233-9936
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | Gerald Falchook, MD (PRINCIPAL_INVESTIGATOR) |
| Sylvester Comprehensive Cancer Center - University of Miami Health System | Miami | Florida | 33136 | Jaime Merchan, MD (PRINCIPAL_INVESTIGATOR) |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Rebecca Heist, MD, MPH (PRINCIPAL_INVESTIGATOR) |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Melissa Johnson, MD (PRINCIPAL_INVESTIGATOR) |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Ecaterina Dumbrava, MD (PRINCIPAL_INVESTIGATOR) |
| NEXT Oncology | San Antonio | Texas | 78229 | David Sommerhalder, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Denver, CO
Nationwide
Breast cancer trialsCervical cancer trialsColorectal cancer trialsEndometrial cancer trialsEsophageal cancer trialsGastric cancer trialsHead and neck cancer trialsLung cancer trialsPancreatic cancer trialsProstate cancer trialsKidney cancer trialsOncology trialsBreast oncology trialsWomen's health trialsGynecologic oncology trialsGI oncology trialsENT trialsLung oncology trialsLung disease trialsProstate oncology trialsMen's health trialsUrology trials
By condition
By specialty
Related Studies
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruiting · Mayo Clinic · Phoenix, Arizona
- Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy ParticipantsRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee
- Collecting and Storing Tissue Samples From Women With or Without Breast CancerRecruiting · Vanderbilt-Ingram Cancer Center · Nashville, Tennessee
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer PatientsRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee